肠道菌群
药理学
毒性
生物
医学
免疫学
内科学
作者
Xinyi Huang,Lulu Chen,Zhenyu Li,Binjie Zheng,Na Liu,Qing Fang,Jinsheng Jiang,Tai Rao,Dongsheng Ouyang
出处
期刊:Toxicology
[Elsevier]
日期:2021-07-14
卷期号:460: 152858-152858
被引量:2
标识
DOI:10.1016/j.tox.2021.152858
摘要
The incidence and mortality of cancer are rapidly growing all over the world. Nowadays, antineoplastic antimetabolites still play a key role in the chemotherapy of cancer. However, the interindividual variations in the efficacy and toxicity of antineoplastic antimetabolites are nonnegligible challenges to their clinical applications. Although many studies have focused on genetic variation, the reasons for these interindividual variations have still not been fully understood. Gut microbiota is reported to be associated with the efficacy and toxicity of antineoplastic antimetabolites. In this review, we summarize the interaction of antineoplastic antimetabolites on gut microbiota and the influences of shifted gut microbiota profiles on the efficacy and toxicity of antineoplastic antimetabolites. The factors affecting the efficacy and toxicity of antineoplastic antimetabolites via gut microbiota are also discussed. In addition, we present our viewpoints that regulating the gut microbiota may increase the efficacy and decrease the toxicity of antineoplastic antimetabolites. This will help us better understand the new mechanism via gut microbiota and promote individualized use of antineoplastic antimetabolites.
科研通智能强力驱动
Strongly Powered by AbleSci AI